The announcement follows widespread speculation in the United Kingdom regarding the potential consolidation of the two biotech entities. While the prospect of a listing on a major American stock exchange has drawn market attention, Neuphoria cautioned that no binding terms have been finalized and there is no guarantee that a transaction will ultimately proceed.

Investors responded with cautious optimism to the news. Neuphoria shares climbed 0.5% to $4.59 during after-hours trading on Friday, building on a 5.1% increase observed during the regular session. The market’s reaction reflects the potential strategic shift for Scancell as it seeks to expand its footprint through this high-profile acquisition.